Trial Search Results
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized phase III trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy.
Stanford is currently accepting patients for this trial.
Lead Sponsor:
Stanford University
Collaborator: National Cancer Institute (NCI)
Stanford Investigator(s):
Intervention(s):
- Drug: Dakin's solution
- Other: Placebo
- Other: Questionnaire Administration
Phase:
Phase 3
Eligibility
Inclusion Criteria:
- Patients with head and neck cancer who plan to undergo radiation therapy to the head
and neck region
- Patients must be at least 18 years of age
- Patients must be able to understand and the willingness to sign a written informed
consent document.
Exclusion Criteria:
- Patients with prior radiation therapy to the head and neck region or prior
chemotherapy for head and neck cancer (induction chemotherapy NOT excluded)
- Patients whose physician-approved radiation treatment plan indicates a maximum
prescription dose of less than 45 Gy
- Patients with scleroderma or discoid lupus
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amanda Simmons
650-724-4606
Recruiting